Media coverage
65
Media coverage
Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet PR Newswire Country/Territory United States Date 17/06/22 Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet Street Insider Country/Territory United States Date 17/06/22 URL https://www.streetinsider.com/Press+Releases/SKYRIZI%C2%AE+%28risankizumab-rzaa%29+Receives+FDA+Approval+as+the+First+and+Only+Specific+Interleukin-23+%28IL-23%29+to+Treat+Moderately+to+Severely+Active+Crohn%27s+Disease+in+Adults/20227121.html Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet BioSpace Country/Territory United States Date 17/06/22 URL https://www.biospace.com/article/releases/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohn-s-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet Yahoo! News Country/Territory United States Date 17/06/22 URL https://www.yahoo.com/now/skyrizi-risankizumab-rzaa-receives-fda-120000225.html Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet ADVFN UK Country/Territory United Kingdom Date 17/06/22 URL https://uk.advfn.com/stock-market/NYSE/ABBV/share-news/SKYRIZI-risankizumab-rzaa-Receives-FDA-Approval-a/88393581 Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet Finanzen.net Country/Territory Germany Date 17/06/22 URL https://www.finanzen.net/nachricht/aktien/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohn-s-disease-in-adults-11455600 Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet MarketScreener.com Country/Territory United States Date 17/06/22 URL https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/SKYRIZI-risankizumab-rzaa-Receives-FDA-Approval-as-the-First-and-Only-Specific-Interleukin-23-IL-40752247/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn’s Disease in Adults Media name/outlet APNews.com Country/Territory United States Date 17/06/22 URL https://apnews.com/press-release/pr-newswire/covid-politics-health-clinical-trials-49f3bb06df0d6153e1b9430812805671 Persons Marla Dubinsky Title SKYRIZI(R) (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet TD Ameritrade Country/Territory United States Date 17/06/22 URL https://research.tdameritrade.com/grid/public/markets/news/story.asp?fromPage=results&docKey=100-168p6983 Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet TickerTech.com Country/Territory United States Date 17/06/22 URL www.tickertech.com/cgi/?a=news&ticker=a&w=&story=202206202206170800PR_NEWS_USPR_____AQ90323 Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn’s Disease in Adults Media name/outlet Market Newsdesk Country/Territory United States Date 17/06/22 URL https://www.marketnewsdesk.com/index.php/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet Markets Business Insider Country/Territory United States Date 17/06/22 URL https://markets.businessinsider.com/news/stocks/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohn-s-disease-in-adults-1031535286 Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet Spoke.com Country/Territory United States Date 17/06/22 URL https://www.spoke.com/press_releases/62ac6d9c04938c08fe001367 Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet PipelineReview Country/Territory Spain Date 17/06/22 URL https://pipelinereview.com/index.php/2022061781084/Antibodies/SKYRIZI-risankizumab-rzaa-Receives-FDA-Approval-as-the-First-and-Only-Specific-Interleukin-23-IL-23-to-Treat-Moderately-to-Severely-Active-Crohns-Disease-in-Adults.html Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA ... Media name/outlet MultiVu.com Country/Territory United States Date 17/06/22 URL https://www.multivu.com/players/English/8978352-abbvie-fda-crohns-disease/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet KOLO TV Reno Country/Territory United States Date 17/06/22 URL https://www.kolotv.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet NBCNebraskaScottsbluff.com Country/Territory United States Date 17/06/22 URL https://www.nbcnebraskascottsbluff.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet WTVM Country/Territory Georgia Date 17/06/22 URL www.wtvm.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet WBAY Green Bay Country/Territory United States Date 17/06/22 URL https://www.wbay.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet WVLT Country/Territory United States Date 17/06/22 URL https://www.wvlt.tv/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet KPLC TV Country/Territory United States Date 17/06/22 URL www.kplctv.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet Webcenter 11 Country/Territory United States Date 17/06/22 URL https://www.webcenterfairbanks.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet My Sun Coast Country/Territory United States Date 17/06/22 URL www.mysuncoast.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet WTOK-TV Country/Territory United States Date 17/06/22 URL https://www.wtok.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet WALB 10 Country/Territory Georgia Date 17/06/22 URL www.walb.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet NewsChannel 10 Country/Territory United States Date 17/06/22 URL www.newschannel10.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet WBKO Country/Territory United States Date 17/06/22 URL https://www.wbko.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet KCBD Country/Territory United States Date 17/06/22 URL www.kcbd.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet WOWT Country/Territory United States Date 17/06/22 URL https://www.wowt.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet Fox 19 Country/Territory United States Date 17/06/22 URL www.fox19.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet WIBW Country/Territory United States Date 17/06/22 URL https://www.wibw.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet Hawaii News Now Country/Territory United States Date 17/06/22 URL www.hawaiinewsnow.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet NBC12 Online Country/Territory United States Date 17/06/22 URL www.nbc12.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet WLOX Country/Territory United States Date 17/06/22 URL https://www.wlox.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet Wave 3 Country/Territory United States Date 17/06/22 URL www.wave3.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet KWTX Country/Territory United States Date 17/06/22 URL https://www.kwtx.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet Upper Michigans Source Country/Territory United States Date 17/06/22 URL https://www.uppermichiganssource.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet WRDW Country/Territory United States Date 17/06/22 URL https://www.wrdw.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet KYTV Country/Territory United States Date 17/06/22 URL https://www.ky3.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet Kgns.tv Country/Territory United States Date 17/06/22 URL https://www.kgns.tv/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet KCRG.com Country/Territory United States Date 17/06/22 URL https://www.kcrg.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet WFMZ-TV Online Country/Territory United States Date 17/06/22 URL https://www.wfmz.com/news/pr_newswire/pr_newswire_health/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il/article_46feb08b-f944-5c39-89fc-1635fc5bba3a.html Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet Cleveland 19 News Country/Territory United States Date 17/06/22 URL https://www.cleveland19.com/prnewswire/2022/06/17/skyrizi-risankizumab-rzaa-receives-fda-approval-first-only-specific-interleukin-23-il-23-treat-moderately-severely-active-crohns-disease-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet VB Profiles Country/Territory United States Date 17/06/22 URL https://www.vbprofiles.com/press_releases/62ac6d90dc613e64e7c6c9fe Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet 8 News Now Country/Territory United States Date 17/06/22 URL https://www.8newsnow.com/news/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet WTen.com Country/Territory United States Date 17/06/22 URL https://www.news10.com/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet ABC 27 Country/Territory United States Date 17/06/22 URL https://www.abc27.com/news/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet CW39 NewsFix Country/Territory United States Date 17/06/22 URL https://cw39.com/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet Everything Lubbock Country/Territory United States Date 17/06/22 URL https://www.everythinglubbock.com/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet FOX 31 News KDVR Country/Territory United States Date 17/06/22 URL https://kdvr.com/news/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet Fox 2 Now Country/Territory United States Date 17/06/22 URL https://fox2now.com/news/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet WKRN Country/Territory United States Date 17/06/22 URL https://www.wkrn.com/news/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet Wood TV Country/Territory United States Date 17/06/22 URL https://www.woodtv.com/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet KFOR.com Country/Territory United States Date 17/06/22 URL https://kfor.com/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet KXAN Country/Territory United States Date 17/06/22 URL https://www.kxan.com/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet KTLA Country/Territory United States Date 17/06/22 URL https://ktla.com/news/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet KRON4 Country/Territory United States Date 17/06/22 URL https://www.kron4.com/news/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet FOX 59 Country/Territory United States Date 17/06/22 URL https://fox59.com/news/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet KOIN Country/Territory United States Date 17/06/22 URL https://www.koin.com/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet WGN-TV Country/Territory United States Date 17/06/22 URL https://wgntv.com/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet NBC4 Columbus Country/Territory United States Date 17/06/22 URL https://www.nbc4i.com/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet WATE Country/Territory United States Date 17/06/22 URL https://www.wate.com/news/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet WKBN 27 First News Country/Territory United States Date 17/06/22 URL https://www.wkbn.com/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet YOUR BASIN Country/Territory United States Date 17/06/22 URL https://www.yourbasin.com/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky Title SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults Media name/outlet FOX5 San Diego Country/Territory United States Date 17/06/22 URL https://fox5sandiego.com/business/press-releases/cision/20220617AQ90323/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults/ Persons Marla Dubinsky